Physician profile
Mark C Thel
NPI 1659370997
$5,000.34
in general payments reported to CMS, 2019-2025
23 companies · $958 in 2025
The $958 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $603 · 2021: $426 · 2022: $794 · 2023: $782 · 2024: $717 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,288.11 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abiomed | $862.04 | 2019-2025 | Impella |
| Abbott Laboratories | $771.44 | 2019-2025 | Mitraclip, Gallant, Xience Skypoint |
| Novartis Pharmaceuticals Corporation | $461.17 | 2019-2025 | |
| Medtronic Vascular, INC. | $346.65 | 2019-2020 | |
| Shockwave Medical, INC | $250.31 | 2020-2025 | |
| Heartflow, INC. | $194.40 | 2025 | |
| Medtronic, INC. | $192.58 | 2021-2024 | Corevalve Evolut R, Telescope |
| Getinge USA Sales, LLC | $119.49 | 2023 | Cardiohelp |
| Amgen INC. | $88.24 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $87.59 | 2022-2024 | |
| Boston Scientific Corporation | $59.00 | 2020-2025 | General - Atherectomy, General - Stents |
| Asahi Intecc USA, INC. | $58.22 | 2020 | |
| Novo Nordisk INC | $40.59 | 2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $32.66 | 2023-2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $30.96 | 2022-2024 | (Br3) Coronary Other |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.99 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $17.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.62 | 2025 | Jardiance |
| Cordis US Corp. | $14.61 | 2024 | Rain Sheath |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Cardiovascular Systems INC. | $13.63 | 2019 | |
| Biosense Webster, INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Thel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.